首页> 外文期刊>International journal of oncology >Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells
【24h】

Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells

机译:siRNA介导的膀胱癌细胞中抗凋亡BCL2,Bcl-xL,XIAP和survivin的敲低

获取原文
           

摘要

Bladder cancer (BCa) represents the ninth most common malignancy worldwide. Despite intensive treatment with surgery and chemotherapy the prognosis for BCa patients particularly at advanced stages is poor. The ability to evade apoptosis is a hallmark of cancer cells. Since the antiapoptotic genes BCL2, Bcl-xL, XIAP and survivin are frequently upregulated in BCa tissues, their combined siRNA-mediated knockdown might be more potent in decreasing BCa growth than the single inhibition of one target. Against each target two siRNAs were selected that specifically reduced the mRNA and protein levels of their appropriate target in EJ28 and J82 BCa cells. Inhibition of survivin provoked the strongest antiproliferative effect of all single target treatments, for example cell counts decreased by 50%. Simultaneous targeting of all four antiapoptotic genes downregulated expression levels of all targets and mediated significant reductions in cell viability and cell counts as well as induction of apoptosis. In EJ28 cells, combined knockdown of BCL2, Bcl-xL, XIAP and survivin caused a 2.5-fold enhancement in apoptosis rate and reduced cellular viability by 40%. Therefore, simultaneous knockdown of antiapoptotic BCL2, Bcl?xL, XIAP and survivin may represent a promising treatment option for bladder cancer.
机译:膀胱癌(BCa)代表全球第九大最常见的恶性肿瘤。尽管通过外科手术和化学疗法进行了深入治疗,但BCa患者的预后尤其是晚期患者仍然很差。逃避凋亡的能力是癌细胞的标志。由于抗凋亡基因BCL2,Bcl-xL,XIAP和survivin在BCa组织中经常被上调,因此它们组合的siRNA介导的敲低可能比单抑制一个靶标更有效地降低BCa的生长。针对每个靶标,选择了两个特异性降低EJ28和J82 BCa细胞中适当靶标的mRNA和蛋白质水平的siRNA。抑制生存素引起了所有单一靶标治疗的最强抗增殖作用,例如细胞数减少了50%。同时靶向所有四个抗凋亡基因会下调所有靶标的表达水平,并介导细胞活力和细胞计数以及诱导凋亡的显着降低。在EJ28细胞中,BCL2,Bcl-xL,XIAP和survivin的组合敲低导致凋亡率提高2.5倍,并使细胞活力降低40%。因此,同时敲除抗凋亡的BCL2,BclαxL,XIAP和survivin可能代表膀胱癌有希望的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号